ArticleFrontiers of medicine2023
Knockdown of RFC4 inhibits the cell proliferation of nasopharyngeal carcinoma in vitro and in vivo.
Article in Frontiers of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 20 citations in OpenAlex.
- Identification of replication factor C subunit 4 as a potential therapeutic target in esophageal squamous cell carcinoma based on bioinformatic analysis and machine learning.Discover oncology · 2026Article
- SMURF1 Regulates CTCF-HOXA10 Axis and Promotes Tumor Progression in Nasopharyngeal Carcinoma.Cancer science · 2026Article
- Multiple roles of replication factor C family in pan‑cancer (Review).Oncology reports · 2025Review
- Charged multivesicular body protein 7 was identified as a prognostic biomarker correlated with metastasis in colorectal cancer.World journal of gastrointestinal oncology · 2025Article
- Shared Genomic Features Between Lung Adenocarcinoma and Type 2 Diabetes: A Bioinformatics Study.Biology · 2025Article
- Article
- Knockdown of RFC4 inhibits cell proliferation of oral squamous cell carcinoma in vitro and in vivo.FEBS open bio · 2025Article
- Comprehensive analysis of RFC4 as a potential biomarker for regulating the immune microenvironment and predicting immune therapy response in lung adenocarcinoma.Frontiers in immunology · 2025Article
- Prognostic significance and pathogenesis of RFC3 gene expression in diffuse large B-cell lymphoma.PeerJ · 2025Article
- Analysis of the correlation between RFC4 expression and tumor immune microenvironment and prognosis in patients with cervical cancer.Frontiers in genetics · 2025Article
- Identification of RFC4 as a potential biomarker for pan-cancer involving prognosis, tumour immune microenvironment and drugs.Journal of cellular and molecular medicine · 2024Article
- Oncogenic and immunological roles of RACGAP1 in pan-cancer and its potential value in nasopharyngeal carcinoma.Apoptosis : an international journal on programmed cell death · 2024Article
- Oncogenic Potential of Replication Factor C Subunit 4: Correlations with Tumor Progression and Assessment of Potential Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2024Article
- ACAT1 promotes proliferation and metastasis of bladder cancer via AKT/GSK3β/c-Myc signaling pathway.Journal of Cancer · 2024Article
- Sophoridine derivative 6j inhibits liver cancer cell proliferation via ATF3 mediated ferroptosis.Cell death discovery · 2023Article
- The expression, immune infiltration, prognosis, and experimental validation of OSBPL family genes in liver cancer.BMC cancer · 2023Article
- Replication Factor C Subunit 4 Plays a Role in Human Breast Cancer Cell Progression.Cancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasopharyngeal carcinoma (NPC) is a malignant tumor that mainly occurs in East and Southeast Asia. Although patients benefit from the main NPC treatments (e.g., radiotherapy and concurrent chemotherapy), persistent and recurrent diseases still occur in some NPC patients. Therefore, investigating the pathogenesis of NPC is of great clinical significance. In the present study, replication factor c subunit 4 (RFC4) is a key potential target involved in NPC progression via bioinformatics analysis. Furthermore, the expression and mechanism of RFC4 in NPC were investigated in vitro and in vivo. Our results revealed that RFC4 was more elevated in NPC tumor tissues than in normal tissues. RFC4 knockdown induced G2/M cell cycle arrest and inhibited NPC cell proliferation in vitro and in vivo. Interestingly, HOXA10 was confirmed as a downstream target of RFC4, and the overexpression of HOXA10 attenuated the silencing of RFC4-induced cell proliferation, colony formation inhibition, and cell cycle arrest. For the first time, this study reveals that RFC4 is required for NPC cell proliferation and may play a pivotal role in NPC tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.